Menu
/REGISTER
Montecito
Nixon Peabody
Pac Premier
Loading...
You are here:  Home  >  Banking & Finance  >  Current Article

Cure Pharmaceutical navigates CBD acquisition, licensing dispute

By   /   Friday, April 9th, 2021  /   No Comments

    Print       Email
Oxnard-based Cure Pharmaceutical saw big rise in revenue in the fourth quarter of 2020 as it integrates a major acquisition, but growing net losses and a dispute with a licensee could be obstacles going forward. Cure closed the acquisition of the CBD company Sera Labs on Oct. 2, according to Cure’s 2020 annual report, filed…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

Leave a Reply

Your email address will not be published. Required fields are marked *

You might also like...

Velocity reports earnings growth, strong loan demand

Read More →